



Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

September 2, 2026

MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences:

- **Cantor Global Healthcare Conference 2026** – management will participate in investor meetings on September 9, 2026.
- **Wells Fargo 21st Annual Healthcare Conference** – management will participate in investor meetings on September 10, 2026.
- **Morgan Stanley 24th Annual Global Healthcare Conference** – management will participate in investor meetings, and Scott Giacobello, Chief Financial Officer, and David Dornan, PhD, Chief Scientific Officer, will participate in a fireside chat on September 15, 2026, at 1:05 PM ET.

A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR [website](#) and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics

Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved cancer treatments. Whitehawk's portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.

Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index. Whitehawk has an option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Any references to the Company's website or other online resources are provided solely for convenience and are not incorporated by reference into this press release. Investors should rely only on the information contained in this press release and the Company's filings with the Securities and Exchange Commission

Contact:

IR@whitehawktx.com



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-upcoming-investor-conferences-302866078.html>

SOURCE Whitehawk Therapeutics, Inc.